NRx Pharmaceuticals (NRXP) Fundamental Analysis: Revenue, Earnings & Valuation

1.78 / 10

Underperform

Fundamental assessment rates the stock at 1.8/10, indicating underperformance. Positive signals arise from accounts receivable turnover and interest coverage, yet fixed‑asset turnover, income‑tax ratio and asset‑to‑market metrics are weak. Overall, the fundamentals are guarded.

Analysis Checks(6/10)

Revenue-MV

Value-3.94

Score3/3

Weight66.25%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight3.52%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-3.76%

1M Return-0.67%

Accounts receivable turnover ratio

Value1.01

Score2/3

Weight-3.73%

1M Return-0.65%

PB-ROE

Value2.67

Score0/3

Weight27.24%

1M Return3.80%

Income tax / Total profit (%)

Value-5.52

Score0/3

Weight-8.47%

1M Return-1.54%

Fixed assets turnover ratio

Value1.13

Score1/3

Weight-6.98%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-4.20%

1M Return-0.73%

Cost of sales ratio (%)

Value40.08

Score2/3

Weight-4.13%

1M Return-0.74%

Asset-MV

Value-0.48

Score0/3

Weight34.26%

1M Return4.88%

Is NRXP fundamentally strong?

NRXP scores 1.78/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -2336.49% net margin, -2.79 P/E ratio, -5.01 P/B ratio, and 43.22% earnings growth, these metrics solidify its Underperform investment rating.